Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Product Launch

18 Nov 2005 07:00

Original Investments PLC18 November 2005 Original Investments PLC ("Original Investments" or "the Company") Commercial product launch from Acrobot Visualisation software, enabling orthopaedic surgeons to producethree-dimensional bone surface models from Computed Tomography (CT) scans forpre-operative surgical planning, is launched today by The Acrobot Company("Acrobot"). Acrobot is a spin-out company from Imperial Innovations, the technologycommercialization company of Imperial College, London, and develops surgicalsystems for minimally-invasive, bone-conserving orthopaedic surgery. TheAIM-quoted company Original Investments (formerly BioProjects International)owns 25% of Acrobot's equity. The new software, called the Acrobot(R) Planner, is Acrobot's first commercialproduct and is being provided free of charge to surgeons who register to use it.Acrobot will receive fees for data preparation and bone modeling. The Acrobot(R) Planner gives the user the ability to visualise a patient's threedimensional bone surface models built from CT scans. The visualisation isinteractive and the user can select and position implant models onto the bones,evaluate the resulting range of motion, and produce reports. "The software will enable surgeons to assess accurately the exact requirementfor each operation and precisely plan the procedure beforehand," says Dr. PaulaGomes, Acrobot's Director of Operations. "It will help to reduce surgicalerrors, surgeon's stress, and overall procedure costs and times. Radiologistswill also use the software to produce enhanced reports." Further uses for the software will be as a powerful tool for teaching and alsogenerating visual material for presentations. Acrobot provides a commercial service for Acrobot(R) Planner users by taking theraw CT DICOM data, segmenting them and building bone surface models from theinformation. The user can import these patient-specific models into thesoftware, and perform hip resurfacing pre-operative surgical planning and/ orimpingement analysis. The data processing service removes the need for the userto be involved in time-consuming routine data preparation tasks. The Acrobot(R) Planner has been developed by the Acrobot team at the company'slaboratories in London's Leathermarket. It is the first of a number of relatedproducts to be produced by Acrobot, which was founded six years ago by ImperialInnovations as a collaboration to combine the skills of clinicians andacademics. Acrobot is initially focusing on developing precision surgical systems forminimally-invasive techniques in knee and hip replacement. With each product theoverall aims are to reduce error, increase accuracy and enable more difficultsculpted surfaces to be achieved for the new generation of 'resurfacing' orpartial joint implants. Products planned for launch in 2006 include the Acrobot(R) Navigation System,which provides visual guidance for the surgeon and is now undergoing regulatoryapproval, and the Acrobot Hands-On Robotic System, which has already beensuccessfully proven in clinic for unicompartmental knee arthroplasty. "We are delighted that our faith in Acrobot is beginning to bear commercialfruit," said Terry Bond, managing director of Original Investments. "Four yearsago we were the first investors outside Imperial College to provide seed-cornfunding for the company and we have continued to support it through the variousstages of its development." Further information on Original Investments PLC from Terry Bond, ManagingDirector, 01235 834734. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
1st Apr 201912:12 pmRNSHolding(s) in Company
25th Mar 20197:00 amRNSYourgene raises IONA® test awareness in Egypt
26th Feb 20193:21 pmRNSHolding(s) in Company
22nd Feb 201910:00 amEQSHardman & Co Research: Yourgene Health (YGEN): EBITDA-positive in fiscal 2020
22nd Feb 20198:05 amRNSHolding(s) in Company
19th Feb 20192:21 pmRNSHolding(s) in Company
19th Feb 20197:15 amEQSHardman & Co Research: Yourgene Health (YGEN): Transformed and de-risked
18th Feb 201910:59 amRNSIssue of Equity
18th Feb 20197:00 amRNSMajor Capital & Commercial Restructuring
8th Jan 20197:00 amRNSYourgene launches Sage 32 plex
3rd Dec 20187:00 amRNSHalf-year Results
7th Nov 20187:00 amRNSChange of Name to Yourgene Health plc
5th Nov 201811:24 amRNSShare Transfer
2nd Nov 20187:00 amRNSDirectorate Change
25th Oct 20183:30 pmRNSResult of AGM
25th Oct 20187:00 amRNSHolding(s) in Company
25th Oct 20187:00 amRNSAGM Statement
22nd Oct 20187:00 amRNSFurther re: Fundraise
12th Oct 20181:15 pmRNSAvailability of Research Commentary
12th Oct 20187:00 amRNSTrading Update and Notice of Results
5th Oct 20187:00 amRNSDirector's dealing and share option issue
4th Oct 20187:00 amRNS$1 million collaboration agreement
3rd Oct 20187:00 amRNSDirectorate change
2nd Oct 20187:00 amRNSNotice of AGM
1st Oct 201812:20 pmRNSResult of Fundraise
28th Sep 20185:41 pmRNSProposed fundraise to raise approximately £2.5m
28th Sep 20185:40 pmRNSFull year results and half-year trading update
25th Sep 201811:31 amRNSHolding(s) in Company
21st Sep 20184:10 pmRNSHolding(s) in Company
21st Sep 20187:00 amRNSHolding(s) in Company
20th Sep 20189:30 amRNSSenior Appointment & Anticipated Director Change
19th Sep 201811:05 amRNSSecond Price Monitoring Extn
19th Sep 201811:00 amRNSPrice Monitoring Extension
19th Sep 20187:00 amRNSLegal Settlement & Licence Agreement with Illumina
11th Sep 20187:00 amRNSHolding(s) in Company
7th Aug 201810:57 amRNSHolding(s) in Company
12th Jul 20187:00 amRNSShare option awards
4th Jul 20187:00 amRNSBoard Changes
26th Jun 20181:31 pmRNSCollaboration with Abnova
13th Jun 20187:00 amRNSOutstanding NIPS Solution Provider Award Win
11th Jun 20187:00 amRNSDNA sequencing technology development agreement
7th Jun 20183:44 pmRNSHolding(s) in Company
5th Jun 20187:00 amRNSPremaitha signs partnership agreement in India
4th Jun 201811:05 amRNSHolding(s) in Company
24th May 20187:00 amRNSHolding(s) in Company
18th May 20184:38 pmRNSHolding(s) in Company
18th May 201812:06 pmRNSHolding(s) in Company
18th May 201812:05 pmRNSHolding(s) in Company
18th May 20189:40 amRNSHoldings in Company
15th May 20187:00 amRNSPremaitha expands footprint with new laboratories

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.